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Role of Gq in smooth muscle cell proliferation
William John Tanski, MD, Elisa Roztocil, BS, Eric A. Hemady, BS, Jacqueline A. Williams, PhD, and
Mark G. Davies, MD, PhD, Rochester, NY
Background: G protein–linked receptors are involved in the processes that lead to intimal hyperplasia. This study
examined the role of Gq signaling pathways in vascular smooth muscle cell (SMC) proliferation in vitro.
Methods: Rat pulmonary artery SMCs were cultured in vitro. Standard assays of cellular DNA synthesis, proliferation,
phospholipase C- (PLC) activation, and extracellular signal-regulated kinase (ERK1/2) phosphorylation were used to
study the response to angiotensin II (a specific Gq agonist; 0.1-100 mol/L) in the presence and absence of GP-2A (a
competitive Gq inhibitor; 10 mol/L) and the PLC inhibitor U73122 (10mol/L).
Results: Angiotensin II induced SMC DNA synthesis and cell proliferation. DNA synthesis was inhibited by both Gq
inhibitor, GP-2A, and PLC inhibitor U73122, in a dose-dependent manner (66%  7% of angiotensin II alone at 10
mol/L for GP-2A [P < .05] and 63%  6% for U73122). GP-2A completely inhibited angiotensin II–induced
Gq-mediated PLC phosphorylation. Activation of ERK1/2 by angiotensin II was significantly reduced by GP-2A (P
< .05) and by PLC inhibition (P < .05).
Conclusion: Inhibition of Gq decreases PLC and ERK1/2 phosphorylation, leading to decreased SMC proliferation in
vitro. Understanding specific signal transduction pathways will be an integral component of anti-restenosis
therapy. (J Vasc Surg 2004;39:639-44.)
Clinical Relevance. The universal response of a blood vessel to injury is chronic wound healing, which includes the
development of intimal hyperplasia and subsequent remodeling of the vessel wall. This can lead to luminal narrowing in
as many as 30% of patients undergoing angioplasty. Neointimal formation is the principal cause of in-stent recurrent
stenosis. Intimal hyperplasia is in part produced by smooth muscle cell (SMC) proliferation. Understanding the keys to
the proliferation of SMCs will enable therapies to be developed that may inhibit the initial development of intimal
hyperplasia. Whereas in the past many studies focused on the multiple mechanical, humoral, and cellular elements that
induce SMC proliferation, molecular therapeutics focuses on key choke points within the cell that can be used to inhibit
proliferation. One of these key choke points is signal transduction. Gq is one of the ubiquitous signal transduction
proteins on the membrane of SMCs. Inhibiting G proteins, such as Gq, would enable interference with a significant
amount of the mechanical, humeral, and cellular elements that produce SMC proliferation, and thus decrease the
development of intimal hyperplasia. The present study identifies and begins to map out the role of Gq in SMC
proliferation and investigates the possible use of a small peptide in its inhibition. Other data suggest that inhibition of
other G proteins will also decrease intimal hyperplasia. This is therefore a fertile area for the development of therapeutics
to inhibit intimal hyperplasia. The direct relevance to the clinician is that this study identifies a transduction pathway that
may be inhibited, and points in the direction of a possible molecular therapeutic target that would be beneficial as an
adjunct to angioplasty or as part of a drug-eluding stent regimen.
Intimal hyperplasia is the universal response of a blood
vessel to injury, causing restenosis in more than 30% of
patients who have undergone angioplasty and posing a
significant economic burden on the health care system.1,2
Intimal hyperplasia is a chronic structural lesion brought
about by smooth muscle cell (SMC) proliferation in the
media and migration to the intima, and the deposition of an
extracellular matrix.3 The precise initiating stimuli for inti-
mal hyperplasia are not fully defined, but appear to involve
the response of vascular SMCs to a combination of physical,
cellular, and humoral factors accompanied by dysfunctional
endothelial regulation.4 Clinically there is no adequate
therapy to treat this lesion. A better understanding of the
cell biology of this process will enable more focused thera-
peutic interventions.
Guanine nucleotide regulatory proteins (G proteins)
are intrinsic membrane-bound proteins that act as trans-
membrane signal transducers in cells. G proteins consist of
three distinct subunits, , , and , and many are classified
according to differences in their G subunits, Gi, Gs,
and Gq. They require conversion of guanine triphosphate
to guanine diphosphate for their activity. We have previ-
ously shown roles for Gi and G in the development of
intimal hyperplasia.5-8 Angiotensin II is a G protein agonist
that activates a Gq-coupled receptor,9 stimulates SMC
proliferation,10,11 and has a significant role in intimal hy-
perplasia.12 In our previous work in both the rat angio-
plasty model8 and the rabbit vein graft model,5 we showed
significant increases in Gq subunit expression. Gq sub-
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units activate phospholipase C (PLC). Activation of G
subunits Gi and Gq results in activation of the extracel-
lular signal-regulated kinase (ERK1/2) pathway.13 The
role of Gq in the development of intimal hyperplasia
requires definition. The present study tests the hypothesis
that the Gq-type G protein is important in vascular SMC
signaling, leading to proliferation, and that this response is
mediated by PLC.
METHODS
Experiment design. Standard assays of cellular DNA
synthesis, proliferation, PLC activation, and ERK1/2
phosphorylation were used. Rat pulmonary arterial SMCs
were used. We examined the efficacy of GP-2A as a Gq
inhibitor, then proceeded to examine its effects on several
G protein–coupled agonists: lysophosphatidic acid (LPA,
10  mol/L, a specific Gi agonist), thrombin (an agonist
that uses both Gi and Gq), and angiotensin II (10 
mol/L, a specific Gq agonist) in the presence and absence
of pertussis toxin (a Gi inhibitor, 100 ng/mL), GP-2 (a
Gi inhibitor, 10 mol/L), and GP-2A (a Gq inhibitor,
10  mol/L). We examined the ability of GP-2A to block
activation of PLC. Finally, we examined the ERK1/2
response to angiotensin II (in the presence and absence of
GP-2A, 10 mol/L) and the PLC inhibitor U73122
(10mol/L).14-16
[3H]thymidine incorporation. The technique used
for [3H]thymidine incorporation has been described in
detail.8 In brief, 24-well cluster dishes (Falcon Plastics,
Madison, SD) were inoculated with 5  104 cells per well
and allowed to reach 70% confluence. The media was
then changed to Dulbecco minimal essential medium;
Gibco, Grand Island, NY) for 2 days to induce cell quies-
cence. The experiments were initiated by adding [3H]thy-
midine (1 Ci/mL; ICN, Irvine, Calif) along with agonists
or pharmacologic inhibitors (see Results for agents and
doses). Incorporation of [3H]thymidine into acid-precipi-
table material was measured after 24 hours of incubation
(air plus 5% carbon dioxide at 37°C). After treatment with
10% trichloracetic acid for 12 hours, sodium hydroxide (0.4
mL, 0.1N) was added, and the dishes were incubated for 60
minutes at room temperature. Aliquots (350 L) were
counted in 5 mL of Cytoscint (ICN Research Products,
Costa Mesa, Calif) with a scintillation counter (Beckman
Instruments, Fullerton, Calif).
Cell proliferation. Culture wells (12-well cluster
dishes; Falcon) were inoculated with 5 104 cells per well
and allowed to attach overnight. Cell counts were deter-
mined on days 1, 3, 5, and 7. Cells from each well were
removed by trypsinization, and the resultant suspension
was counted with a hemocytometer (Hausser Scientific,
Horsham, Pa).8
Immunoprecipitation for PLC. Time courses of
angiotensin II–induced PLC activation were performed in
the presence and absence of GP-2A (10 mol/L). PLC
was immunoprecipitated from total cell extracts with a
polyclonal antibody (Upstate Biotechnology, Lake Placid,
NY) according to the manufacturer’s instructions. Immu-
nocomplexes were then collected with protein A–Sepha-
rose beads (Pharmacia Biotech, Piscataway, NJ), washed
several times with Tween 20 in phosphate-buffered saline
solution (Cellgro, Herndon, Va), fractionated with so-
dium dodecylsulfate–polyacrylamide gel electrophoresis,
and probed with PY20 for tyrosine phosphorylation
protein.
Western blot analysis. The technique for in vitro cell
stimulation and Western blot analysis for phosphorylated
and total ERK1/2 has been described in detail.17 In brief,
SMCs at 80% confluence were starved for 24 hours, stimu-
lated with agonists alone or with inhibitors, and harvested
(see Results for agonists, inhibitors, and time points). The
suspension was sonicated (MSE, Pittsburgh, Pa), and pro-
tein determinations were performed with a bicinchonic acid
assay (Pierce Chemical, Rockford, Ill) with bovine serum
albumin as the standard. Equal amounts of protein lysates
(25 g) were loaded onto 12.5% polyacrylamide gels, sep-
arated with electrophoresis, and transferred to nitrocellu-
lose membranes (Biorad Laboratories, Richmond, Calif).
After blocking in 5% nonfat milk, blots were immuno-
stained with antibodies against phosphorylated or total
ERK1/2. Protein bands were visualized with anti-rabbit
(phospho-ERK) or anti-mouse (total ERK) immunoglob-
ulin G horseradish peroxidase–conjugated antibodies, fol-
lowed by enhanced chemiluminescence (Amersham, Ar-
lington Heights, Ill), with the manufacturer’s protocols.
Band intensity was measured with densitometry with Gel-
Imaging software (Kodak, Rochester, NY). All experiments
were performed at least three times.18
Data and statistical analysis. All data are presented as
the mean  SEM. Statistical differences between groups
were tested with a Kruskal-Wallis nonparametric test with
post hoc Dunn multiple comparison correction, where
appropriate. P  .05 was regarded as significant. Non-
significant P values are expressed as P 	 NS.
Fig 1. In vitro [3H]thymidine incorporation into DNA of cultured
vascular smooth muscle cells in response to fetal bovine serum
(10%) in the presence of increasing concentrations of GP-2A
(0.1-100 mol/L). Values represent mean  SEM of percent of
control for six experiments.
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RESULTS
GP-2A as Gq inhibitor. To assess the role of the
Gq inhibitor GP-2A in cell proliferation, cultured rat
vascular SMCs were stimulated with fetal bovine serum
(10%) in the presence and absence of increasing concentra-
tions of GP-2A (0.1-100 mol/L). Stimulation with se-
rum resulted in a 6.1-fold increase in DNA synthesis com-
pared with unstimulated cells. The inhibitory effect of
GP-2A on serum-induced thymidine incorporation was
dose-dependent, with an inhibitory concentration of 50%
(IC50) for inhibition at 10 mol/L (Fig 1). To determine
the specificity of GP-2A for Gq signaling, we examined
the responses of SMCs to stimulation of a series of G
protein–coupled receptors: LPA, a Gi agonist), thrombin
(a mixed Gi and Gq agonist), and angiotensin II (a Gq
agonist). GP-2A had no effect on LPA-induced DNA
synthesis, a partial inhibitory effect on thrombin-induced
DNA synthesis, and a significant inhibitory effect on angio-
tensin II–induced DNA synthesis (Fig 2). The effect was
distinct from that with the Gi inhibitors, GP-2, and
pertussis toxin, which inhibited LPA responses and only
partially inhibited thrombin responses. Given the specificity
of GP-2A for Gq and angiotensin II–mediated responses,
we chose to use angiotensin II as the sole agonist in
subsequent experiments.
Cell proliferation in response to angiotensin II in
SMCs. Angiotensin II produced a dose-dependent in-
crease in DNA synthesis. This response was inhibited by
GP-2A (Fig 3, A). GP-2A also significantly inhibited SMC
proliferation induced by angiotensin II, as measured by
manual counting over 7 days (Fig 3, B). In the presence of
U73122, a specific PLC inhibitor, DNA synthesis and cell
proliferation in response to angiotensin II was inhibited
(Fig 3, A). Furthermore, the addition of a specific inhibitor
of mitogen-activated protein kinase 1 (MEK1, the up-
stream regulator of ERK1/2), PD98059, significantly re-
duced both DNA synthesis (Fig 3, A) and cell proliferation
in response to angiotensin II (data not shown; P  .05).
PLC signaling of angiotensin II in SMCs. The
data confirm that angiotensin II can mediate its responses
through a Gq-linked receptor and that activation of PLC
is involved. To confirm that PLC is activated in a Gq-
dependent manner by angiotensin II, we examined the
activation of PLC with immunoprecipitation of the phos-
phorylated form of PLC in the presence and absence of
GP-2A. Angiotensin II stimulated biphasic phosphoryla-
tion of PLC, which was inhibited by GP-2A (Fig 4).
GP-2A alone had no effect.
ERK1/2 signaling of angiotensin II in SMCs. An-
giotensin II–mediated cell proliferation is MEK1-depen-
dent. Angiotensin II activated ERK1/2 in a time-depen-
dent manner (Fig 5). This ERK1/2 activation by
angiotensin II was inhibited by GP-2A (54% inhibition
compared with angiotensin II alone;, P  .05) and by the
PLC inhibitor U73122.
DISCUSSION
This report demonstrates that angiotensin II mediates
its proliferative responses in part through the activation of
Gq protein–induced PLC activation and that this re-
sponse is ERK1/2-mediated. It also illustrates the efficacy
of the novel Gq protein inhibitor GP-2A on these re-
sponses.
G proteins and intimal hyperplasia. The formation
of intimal hyperplasia involves SMC proliferation and mi-
gration, followed by intimal expansion with extracellular
Fig 2. In vitro [3H]thymidine incorporation into DNA of cultured vascular smooth muscle cells in response to
lysophosphatidic acid (LPA; 10 mol/L), thrombin (100 U/mL), and angiotensin II (100 mol/L) in the presence
and absence of pertussis toxin (a Gi inhibitor, 100 ng/mL), GP-2 (a Gi inhibitor, 10 mol/L), and GP-2A (a Gq
inhibitor, 10 mol/L). Values represent mean SEM of percent of control for six experiments. **P .05 vs agonist
alone.
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matrix synthesized by SMCs and intimal remodeling.19
Signaling within the vessel wall is required for this pro-
grammed series of events. While much has been deter-
mined in vitro, relatively little is known about these signal-
ing cascades in the vessel wall after injury. We have
concentrated on G protein signal transduction systems as
possible targets for molecular therapeutic agents. We have
shown in models of both vein grafting and artery balloon
injury that there are changes in the expression of G proteins
within the vessel wall.5,8 In particular, we demonstrated
increased expression of Gi, G, and Gq subunits. All
three are linked to pro-proliferative pathways and are cou-
pled to multiple receptors for known mitogens.9 We have
previously demonstrated that inhibition of Gi subunits
with pertussis toxin or interference with G signaling
reduces SMC proliferation in vitro and in vivo.8,20 In vein
grafts, -adrenergic responses were effectively inhibited by
Gi blockade (with pertussis toxin), whereas serotonergic
responses were only partially decreased by pertussis toxin,
which suggests that Gq may have a role.5
The present study shows that Gq is involved in SMC
proliferation and that the Gq peptide inhibitor GP-2A
decreases DNA synthesis and cell proliferation in vitro. It
also demonstrates that this response is mediated by PLC
and ERK1/2 activation. Angiotensin II is both a mitogen
and a hypertrophic factor for SMCs,4 and although Gq is
involved in the proliferation of SMCs in vitro, in vivo it may
well be more important in the hypertrophic response that
occurs in vascular SMCs. Most of these responses depend
on the angiotensin II type 1 receptor.21 Data from our vein
grafting studies support such a contention.21 We inhibited
angiotensin II type 1 receptor over both the short term and
the long term, and demonstrated that intimal hyperplasia is
inhibited by short-term application in the vein grafts and
that medial hypertrophy is inhibited by long-term applica-
tion.22,23 These data thus suggest that Gq may be in-
volved early and late in the intimal hyperplastic process.
Gq. G proteins are involved in the signal transduc-
tion processes of seven membrane-spanning receptors, such
as angiotensin II, and the angiotensin II type 1 receptor is
associated with Gq proteins.24 The Gq family of G
proteins mediate receptor stimulation of PLC activity at
the plasma membrane. PLC and regulators of G protein
signaling function as guanine triphosphatase activating ki-
nases on Gq to control the amplitude and duration of
stimulation.25 These activities can be blocked by G
subunits.26 Receptor activation of PLC via G proteins
occurs by means of pertussis toxin–sensitive and pertussis
toxin–insensitive signaling pathways. The  subunits of the
Gq family are presumed to mediate the toxin-sensitive
pathway, while the G subunits mediate toxin-insensitive
activation.27 Our data are consistent with these proposed
mechanisms of G protein PLC interactions, and demon-
strate that GP-2A can effectively inhibit PLC phosphoryla-
tion and reduce ERK1/2 activation. However, angiotensin
II can mediate ERK1/2 activation through the Gq sub-
unit in two ways, through activation of PLC and by
Fig 3. A, In vitro [3H]thymidine incorporation into DNA of
cultured vascular smooth muscle cells in response to angiotensin II
(100 mol/L) in the presence and absence of GP-2A (a Gq
inhibitor, 10 mol/L), U73122 (a PLC inhibitor, 10 mol/L),
and PD98059 (a MEK1 inhibitor, 10 mol/L). Values represent
mean SEM of percent of control for six experiments. *P .05 vs
agonist alone. B, In vitro proliferation of cultured vascular smooth
muscle cells after stimulation with angiotensin II (100 mol/L) in
the presence and absence of GP-2A (10 mol/L). Values repre-
sent mean SEM of fold increase over control for six experiments.
Fig 4. Time course of PLC phosphorylation in cultured vascular
smooth muscle cells in response to angiotensin II (100mol/L) in
the presence and absence of GP-2A (10 mol/L). Values repre-
sent mean  SEM of fold increase in PLC phosphorylation over
control cells, as measured with densitometry, for three experi-
ments.
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transactivation of the epidermal growth factor receptor.28
The data presented in this article confirm that the first
pathway is viable in SMCs, and we have shown that incu-
bation with an epidermal growth factor receptor kinase
inhibitor (AG1478) will also inhibit ERK1/2 signaling
(unpublished data), supporting the dual-pathway hypoth-
esis. A confounding factor, which we have not addressed in
this report, is the role of G in angiotnsin II–Gq-PLC-
ERK1/2 signaling. G are separate signaling molecules
that can induce ERK1/2 activation and can also interact
with PLC to moderate its activity. The biphasic response
we identified with PLC may be explained by this effect.
Activation of a G subunit is required to liberate a G
subunit. Its abolition in the presence of Gq inhibition
would suggest that both Gq and G effects are affected.
PLC. The receptor-regulated PLC pathway is an
important component in signaling cascades that regulate
cell function. It can be activated by both G protein–cou-
pled receptor agonists (eg, angiotensin II, bradykinin) and
by receptor-linked tyrosine kinase agonists (eg, platelet-
derived growth factor).29 PLC exists as a dimer that
mediates its interactions with Gq.30 Stimulation of PLC
activity results in rapid hydrolysis of phosphatylinosital-4-
5-bisphosphate, with production of inosital-1.4.5 triphos-
phate and diacylglycerol, which increase intracellular cal-
cium and activate protein kinase C. Activation of the Gq-
linked PLC pathway generates other signaling lipids that
can regulate the activity or localization of numerous intra-
cellular proteins. PLC1 and PLC are expressed in human
aortic vascular SMCs, and PLC1 appears to be the isoform
critical for angiotensin II–regulated PLC signaling in these
cells.31
There are very limited data on the role of PLC in
intimal injury. Within 24 hours of balloon injury in the rat
aorta, PLC activity is not significantly increased, but by 14
days PLC activity has increased twofold.32 The role on PLC
inhibition has not been addressed in vivo to date. The data
presented here suggest that PLC inhibition should induce a
decrease in intimal hyperplasia through a decrease in cell
proliferation.
Conclusion. Gq G proteins mediate proliferative re-
sponses in SMCs in part through the activation of PLC,
and this response is ERK1/2-mediated. The data also
illustrate the efficacy of the novel inhibitory peptide inhib-
itor GP-2A on these responses. Further definition of the
Gq pathways that lead to ERK1/2 activation, and trans-
lation into an in vivo model are required.
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